One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2021-147607
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 9 |
Affiliation: Princess Margaret Cancer Centre, University of Kansas, The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at San Antonio, St Thomas' Hospital, Policlinico San Matteo Fondazione, Istituti di Ricovero e Cura a Carattere Scientifico, Hôpital Saint-Louis, Fred Hutch Cancer Center, Allegheny Health Network, University of British Columbia, UW Carbone Cancer Center, Saint Agnes Hospital, Avera Health, Bristol-Myers Squibb (United States), University of Michigan–Ann Arbor
Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
